4Windecker S, Kolh P, Alfonso F, et ol. 2014 ESC/EACTS Guidelines onmyocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of theEuropeanAssociation of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014 Aug 29. pii: ehu278.
5Hart JY,Fan JY,Hode YAmeliorating effects ofcompounds derived from Salvia miltiorrhiza root extract a 11 mierocirculatory disturbance and target organ injury by ischemia and reperfusion. [J].Pharmacol Ther, 2008,117 (2) : 280.295.
6Ndrepepa G 1 ,Tiroch K, Fusaro M ,et al.5-year prognostic value of no -re 10w phenomenon after percutaneous coronary intervention in patients with acute yocardial infarction [J].J A m Coil Cardiol,2010,55(21 ) : 2383.
7Ji DB, Zhu MC ,Zhu B,et al.Hydroxyl safflor yellow A enhances survival of vascular endothelial cells under hypoxia via up- regulation of the HIF-lct - VEGF pathway and regulation of Bcl-2 / Bax[J]. J Cardiovasc Pharmacol, 2008,52 (2) : 191-202.
8Wang SL,Wang CL,Wang PL,et al.Combination of Chinese herbal medicines and conventional treatment versus conventional treatment alone in patients with acute coronary syndrome after percutaneous coronary intervention (5C Trial):an open-label randomized controlled, multicenter study [J].Evid-Based Compl Alt , 2013, 2013(1):1-8.
